Thousand Oaks dermatology biotech firm Dyve Biosciences got the nod from regulators to send its topical pain and gout treatment through Phase 2 trials. The privately held firm announced Dec. 9 that additional clinical trials of its product, DYV-700, had been approved by the U.S. Food and Drug Administration, and are planned to begin in…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
